{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:09:01Z","timestamp":1791328141119,"version":"4.3.1"},"reference-count":82,"publisher":"European Respiratory Society (ERS)","issue":"143","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2016,8,28]]},"published-print":{"date-parts":[[2017,3,31]]},"abstract":"<jats:p>Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20\u2005years since the introduction of this prostacyclin analogue, the outlook for patients with PAH has improved, with survival rates now double those from the era before the development of disease-specific treatments. Today, there are a large amount of data on the clinical role of prostacyclin treatments and a body of evidence attesting the efficacy of epoprostenol in improving exercise capacity, key haemodynamic parameters and PAH symptoms, as well as in reducing mortality. The place of epoprostenol in the therapeutic management of PAH continues to evolve, with the development of new formulations and use in combination with other drug classes. In this review, we provide a historical perspective on the first 20\u2005years of epoprostenol, a therapy that led to evidence-based study of PAH-specific treatments and the subsequent expansion of treatment options for PAH.<\/jats:p>","DOI":"10.1183\/16000617.0055-2016","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T02:46:59Z","timestamp":1484794019000},"page":"160055","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":93,"title":["Epoprostenol and pulmonary arterial hypertension: 20\u2005years of clinical experience"],"prefix":"10.1183","volume":"26","author":[{"given":"Olivier","family":"Sitbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Vonk Noordegraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"2024102403251552000_26.143.160055.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701093360207"},{"key":"2024102403251552000_26.143.160055.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035488"},{"key":"2024102403251552000_26.143.160055.3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MAJ.0b013e31815d2647","article-title":"Pulmonary arterial hypertension","volume":"335","author":"Highland","year":"2008","journal-title":"Am J Med Sci"},{"key":"2024102403251552000_26.143.160055.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.01.024"},{"key":"2024102403251552000_26.143.160055.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2024102403251552000_26.143.160055.6","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005587"},{"key":"2024102403251552000_26.143.160055.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00042107"},{"key":"2024102403251552000_26.143.160055.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"2024102403251552000_26.143.160055.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.031"},{"key":"2024102403251552000_26.143.160055.10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/17425250802622962","article-title":"Epoprostenol in pulmonary arterial hypertension","volume":"5","author":"Jacobs","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2024102403251552000_26.143.160055.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024102403251552000_26.143.160055.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2024102403251552000_26.143.160055.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"2024102403251552000_26.143.160055.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.488486"},{"key":"2024102403251552000_26.143.160055.15","doi-asserted-by":"crossref","unstructured":"Barst R . How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? Int J Clin Pract Suppl 2010;: 23\u201332.","DOI":"10.1111\/j.1742-1241.2010.02525.x"},{"key":"2024102403251552000_26.143.160055.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-7-485"},{"key":"2024102403251552000_26.143.160055.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2024102403251552000_26.143.160055.18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2024102403251552000_26.143.160055.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.10.009"},{"key":"2024102403251552000_26.143.160055.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200110-028PP"},{"key":"2024102403251552000_26.143.160055.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.01.035"},{"key":"2024102403251552000_26.143.160055.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.11.002"},{"key":"2024102403251552000_26.143.160055.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"2024102403251552000_26.143.160055.24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.4.1293"},{"key":"2024102403251552000_26.143.160055.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00116313"},{"key":"2024102403251552000_26.143.160055.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00097107"},{"key":"2024102403251552000_26.143.160055.27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0005-5"},{"key":"2024102403251552000_26.143.160055.28","unstructured":"GSK. Flolan Summary of Product Characteristics. www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Flolan\/pdf\/FLOLAN-PI-PIL.PDF Date last updated: April 2015. Date last accessed: September 20, 2015."},{"key":"2024102403251552000_26.143.160055.29","doi-asserted-by":"publisher","DOI":"10.1038\/263663a0"},{"key":"2024102403251552000_26.143.160055.30","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(76)90126-X"},{"key":"2024102403251552000_26.143.160055.31","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(78)90004-X"},{"key":"2024102403251552000_26.143.160055.32","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(76)90047-2"},{"key":"2024102403251552000_26.143.160055.33","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"2024102403251552000_26.143.160055.34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"2024102403251552000_26.143.160055.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80377-4"},{"key":"2024102403251552000_26.143.160055.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270202"},{"key":"2024102403251552000_26.143.160055.37","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.25.3266"},{"key":"2024102403251552000_26.143.160055.38","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2001.119329"},{"key":"2024102403251552000_26.143.160055.39","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1016\/S0021-9258(17)32663-7","article-title":"Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells","volume":"269","author":"Prins","year":"1994","journal-title":"J Biol Chem"},{"key":"2024102403251552000_26.143.160055.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.038"},{"key":"2024102403251552000_26.143.160055.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00187-3"},{"key":"2024102403251552000_26.143.160055.42","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029100.82385.58"},{"key":"2024102403251552000_26.143.160055.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.313"},{"key":"2024102403251552000_26.143.160055.44","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081277"},{"key":"2024102403251552000_26.143.160055.45","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-6-199409150-00003"},{"key":"2024102403251552000_26.143.160055.46","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200204-333OC"},{"key":"2024102403251552000_26.143.160055.47","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.80.2.151"},{"key":"2024102403251552000_26.143.160055.48","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.70.4.366"},{"key":"2024102403251552000_26.143.160055.49","first-page":"230","article-title":"[Ten years\u2019 experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension]","volume":"56","author":"Pombo Jimenez","year":"2003","journal-title":"Rev Esp Cardiol"},{"key":"2024102403251552000_26.143.160055.50","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","article-title":"Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study","volume":"13","author":"Humbert","year":"1999","journal-title":"Eur Respir J"},{"key":"2024102403251552000_26.143.160055.51","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X"},{"key":"2024102403251552000_26.143.160055.52","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3109\/s10165-012-0828-1","article-title":"Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center","volume":"23","author":"Shirai","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2024102403251552000_26.143.160055.53","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.1.14"},{"key":"2024102403251552000_26.143.160055.54","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.healun.2010.05.011","article-title":"Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era","volume":"29","author":"Jacobs","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"2024102403251552000_26.143.160055.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380501"},{"key":"2024102403251552000_26.143.160055.56","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann Intern Med"},{"key":"2024102403251552000_26.143.160055.57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300307"},{"key":"2024102403251552000_26.143.160055.58","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21174"},{"key":"2024102403251552000_26.143.160055.59","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.25358"},{"key":"2024102403251552000_26.143.160055.60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.mpg.0000178441.10417.0f","article-title":"Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol","volume":"41","author":"Laving","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024102403251552000_26.143.160055.61","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199802270-00001"},{"key":"2024102403251552000_26.143.160055.62","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.26057"},{"key":"2024102403251552000_26.143.160055.63","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)03328-3"},{"key":"2024102403251552000_26.143.160055.64","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1164\/ajrccm.162.5.2004042","article-title":"Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension","volume":"162","author":"Aguilar","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403251552000_26.143.160055.65","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200204-330OC"},{"key":"2024102403251552000_26.143.160055.66","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.040618"},{"key":"2024102403251552000_26.143.160055.67","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404"},{"key":"2024102403251552000_26.143.160055.68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2007.01176.x"},{"key":"2024102403251552000_26.143.160055.69","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.9.734"},{"key":"2024102403251552000_26.143.160055.70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.healun.2008.12.003","article-title":"Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy","volume":"28","author":"Jacobs","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"2024102403251552000_26.143.160055.71","doi-asserted-by":"publisher","DOI":"10.4037\/ccn2013290"},{"key":"2024102403251552000_26.143.160055.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.03.008"},{"key":"2024102403251552000_26.143.160055.73","doi-asserted-by":"crossref","unstructured":"Doran AK , Ivy DD , Barst RJ , et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008(160): 5\u20139.","DOI":"10.1111\/j.1742-1241.2008.01811.x"},{"key":"2024102403251552000_26.143.160055.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.08.007"},{"key":"2024102403251552000_26.143.160055.75","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110687"},{"key":"2024102403251552000_26.143.160055.76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/DDDT.S29916","article-title":"Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"2024102403251552000_26.143.160055.77","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.clinthera.2013.02.013","article-title":"Comparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy men","volume":"35","author":"Nicolas","year":"2013","journal-title":"Clin Ther"},{"key":"2024102403251552000_26.143.160055.78","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ahj.2013.08.008","article-title":"Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study","volume":"167","author":"Chin","year":"2014","journal-title":"Am Heart J"},{"key":"2024102403251552000_26.143.160055.79","unstructured":"Actelion. VELETRI\u00ae Summary of Product Characteristics. www.veletri.com\/ Date last updated: June 2012. Date last accessed: December 1, 2015."},{"key":"2024102403251552000_26.143.160055.80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120657"},{"key":"2024102403251552000_26.143.160055.81","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0029-0"},{"key":"2024102403251552000_26.143.160055.82","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1378\/chest.14-1004","article-title":"Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study","volume":"147","author":"Frantz","year":"2015","journal-title":"Chest"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0055-2016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:59:08Z","timestamp":1740373148000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0055-2016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":82,"journal-issue":{"issue":"143","published-online":{"date-parts":[[2017,1,17]]},"published-print":{"date-parts":[[2017,3,31]]}},"alternative-id":["10.1183\/16000617.0055-2016"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0055-2016","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]}}}